Product Name:1-{[4-(hydroxymethyl)phenyl]methyl}-1,2-dihydropyridin-2-one

IUPAC Name:1-{[4-(hydroxymethyl)phenyl]methyl}-1,2-dihydropyridin-2-one

CAS:1564668-60-5
Molecular Formula:C13H13NO2
Purity:95%+
Catalog Number:CM1045566
Molecular Weight:215.25

Packing Unit Available Stock Price($) Quantity

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:1564668-60-5
Molecular Formula:C13H13NO2
Melting Point:-
Smiles Code:OCC1=CC=C(CN2C=CC=CC2=O)C=C1
Density:
Catalog Number:CM1045566
Molecular Weight:215.25
Boiling Point:
MDL No:
Storage:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Sebetralstat
KalVista Pharmaceuticals recently announces Phase 3 KONFIDENT trial of Sebetralstat meets all primary and key secondary endpoints as first oral on-demand therapy for Hereditary Angioedema (HAE). HAE is a rare and potentially life-threatening genetic disease caused by low levels or dysfunction of the C1 inhibitor, associated with uncontrolled plasma kallikrein (PKa) activity and generation of bradykinin (BK).
Sebetralstat is an investigational novel, oral plasma kallikrein inhibitor with a favorable safety profile. It works by targeting the kallikrein–kinin system (KKS), reducing the activity of plasma kallikrein and blocking uncontrolled bradykinin release in HAE attack. The Phase 3 results also show rapid symptom relief in a broad HAE population.

Related Products